US › Healthcare

Aligos Therapeutics Inc (ALGS)

US · Healthcare · Biotechnology

$4.86-9.83%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$27.8M

Revenue YoY

+2778.5%

Net profit

$-1.5M

EPS

$-0.14

EPS estimate

$-1.41

Net margin

-5.4%

EPS came in at -0.14 against a street estimate of -1.41 — a beat of 90.1%.

Key statistics

Market cap

$33.2M

Forward P/E

0.0

P/B

1.09

Book value

$5.11

EPS (TTM)

$-7.33

52-week high

$13.69

52-week low

$3.98

50-day MA

$5.87

200-day MA

$6.59

Beta

2.36

Analyst view

Analysts rate Aligos Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $52.38.

Shareholding

Insiders

10.64%

Institutions

42.16%

Largest institutional holders

Fund	Stake
Deep Track Capital, LP	7.11%
Alyeska Investment Group, L.P.	6.60%
Sio Capital Management, LLC	5.24%
Marshall Wace Asset Management Ltd	3.95%
Woodline Partners LP	2.84%
Vanguard Capital Management, LLC	2.81%
Baker Bros Advisors LP	1.33%
Hillhouse Capital Advisors, Ltd.	1.22%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aligos Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.